ReNeuron welcomes European Parliament support for Advanced Therapies Regulation. 26/04/07
Guildford, UK, 25 April 2007: ReNeuron Group plc (LSE: RENE.L) welcomes today’s vote by the European Parliament to create a regulatory framework and single European marketing authorisation for gene therapy, cell therapy and tissue engineered products. MEPs voted in favour of a compromise package of amendments and Parliament rejected all ethical amendments banning products derived from human embryonic stem cells from the scope of the Regulation. These amendments significantly increase the possibility of early adoption of the Regulation. The Regulation will harmonise patient access to innovative treatments in Europe by removing the hurdles created by the many differing regulatory systems across the Continent.
More…
ReNeuron receives notice of European patent grant covering key neural stem cell lines. 17/04/07
ReNeuron receives notice of European patent grant covering key neural stem cell lines
Guildford, UK, 17 April 2007: ReNeuron Group plc (LSE: RENE.L) today announced that it has received a notification of grant from the European Patent Office concerning a patent application covering the composition, manufacture and use of three key human neural stem cell lines.
More…
ReNeuron to present at Stem Cell 2007 conference in Germany. 06/03/07
ReNeuron Group plc (LSE: RENE.L) today announces that its Chief Executive Officer, Michael Hunt, will present an overview of the Company’s stem cell technologies and programmes at the “Stem Cell 2007 � Stem Cell Industry Meets Investors” conference being held at the Steigenberger Hotel Frankfurter Hof, Frankfurt, Germany on 8-9 March. The presentation is scheduled for Thursday 8 March at 11:10am local time.
More…
ReNeuron gains revenue-share on new cell line patent. 26/02/07
Guildford, UK, 26 February 2007: ReNeuron Group plc today announces that it has entered into a revenue-sharing agreement with the international Ludwig Institute of Cancer Research (LICR) and the Dana-Farber Cancer Institute, Boston, US, concerning newly-patented research conducted by these institutions on certain gene-based somatic cell expansion technology.
More…
Allotment of shares. 16/02/07
Guildford, UK, 16 February 2007: ReNeuron Group plc announces the proposed issue to StemCells, Inc. (SCI) of 62,543 new ordinary shares of 1p each fully paid up as to nominal value. The issue of shares to SCI shall be made on 19 February 2007 in final satisfaction of the Company’s obligations under a subscription and share exchange agreement between, inter alia, the Company and SCI dated 5 July 2005 (as amended). No further shares are due to be issued to SCI pursuant to such agreement.
More…
ReNeuron to Present at 2nd Annual Stem Cell Summit. 14/02/07
Guildford, UK, 12 February 2007: ReNeuron Group plc (LSE: RENE.L) today announces that its Founder and Chief Scientific Officer, Dr. John Sinden, will present an overview of the Company’s leading edge stem cell technologies and programmes at the 2nd Annual Stem Cell Summit being held at the Wyndham at Emerald Plaza San Diego in San Diego, California. The presentation is scheduled for Monday, February 12, 2007 at 2:45 PM PST.
More…
ReNeuron announces £5.5 million fundraising. 06/02/07
Guildford, UK, 6 February 2007: ReNeuron Group plc today announces that it proposes to place 18,333,333 new ordinary shares of 1p each credited as fully paid at a price of 30p per share, to raise £5.5 million before expenses. Collins Stewart Europe Limited acted as nominated adviser and broker to the Company in connection with the placing.
More…
ReNeuron secures funding from Michael J. Fox Foundation for ReN004 stem cell therapy for Parkinson's disease. 24/01/07
Guildford, UK, 24 January 2007: ReNeuron Group plc (LSE: RENE) today announces that it has been awarded a grant from the US-based Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop its ReN004 stem cell therapy for Parkinson’s disease. The award was made under MJFF’s Therapeutics Development Initiative, designed to catalyse and expand industry investment in pre-clinical Parkinson’s drug development.
More…
Regulatory Update. 12/01/07
Guildford, UK, 12 January 2007: ReNeuron Group plc (LSE: RENE) today provides a further update regarding its recently filed Investigational New Drug (IND) application to commence a Phase I clinical study for its ReN001 stem cell therapy for stroke.
More…
Regulatory Update. 09/01/07
Guildford, UK, 9 January 2007: ReNeuron Group plc (LSE: RENE) today provides an update regarding its recently filed Investigational New Drug (IND) application to commence a Phase I clinical study for its ReN001 stem cell therapy for stroke. The US Food and Drug Administration (FDA) has orally confirmed that it has placed the proposed clinical study on hold. A telephone conference call with the FDA to discuss the application is expected to take place later this week, following which the Company will make a further announcement.
More…
